These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Completed, but no date Terminated||2004-001035-32||NON-MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM HLA IDENTICAL SIBLING FOR METASTATIC SOFT TISSUE SARCOMAS||bad-data|
|Listed as ongoing, but also has a completion date and reported results||2004-001810-16||Intermediate and high risk localized , completely resected, gastrointestinal stromal tumors ( GIST) expressing KIT receptor: a controlled randomized trial on adjuvant Imatinib mesylate ( Glivec) versu...||2017-07-12||bad-data|
|Ongoing||2006-006446-33||Open-label trial of Imatinib in patients with Desmoid Tumor and Chondrosarcoma||not-yet-due|
|Listed as ongoing, but also has a completion date||2007-002257-23||A phase III randomized study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumor responding to Imatinib mesylate.||2011-03-11||bad-data|
|Ongoing||2007-004396-19||Phase II, open label, non-randomized study of second or third line treatment with sorafenib (BAY 43-9006) in patients affected by relapsed high-grade osteosarcoma.||not-yet-due|
|Listed as ongoing, but also has a completion date||2010-023484-17||LOCALIZED HIGH-RISK SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND TRUNK WALL IN ADULTS: AN INTEGRATING APPROACH COMPRISING STANDARD VS HISTOTYPE-TAILORED NEOADJUVANT CHEMOTHERAPY (ISG-STS 10-01)||2016-05-26||bad-data|
|Not reported||2011-000561-12||A phase II, open label, non-randomized study of second or third line treatment with the combination of sorafenib and everolimus in patients affected by relapsed and non-resectable high-grade osteos...||2015-06-19||due-trials|
|Ongoing||2011-001659-36||ABCB1/P-glycoprotein as biological marker for treatment of patient with high grade osteosarcoma||not-yet-due|
|Completed, but no date Terminated||2012-001010-42||A multicenter, prospective, randomized clinical trial for patients with relapsed osteosarcoma||bad-data|
|Ongoing||2012-005428-14||A Phase II study on Trabectedin in advanced retroperitoneal leiomyosarcoma and well differentiated/dedifferentiated liposarcoma||not-yet-due|
|Ongoing||2013-001467-23||SAFETY AND ACTIVITY OF TRABECTEDIN AS FIRST LINE IN ADVANCED SOFT TISSUE SARCOMA (STS) PATIENTS UNFIT TO RECEIVE STANDARD CHEMOTHERAPY: A PROSPECTIVE PHASE II STUDY WITH CLINICAL AND MOLECULAR CORRELA...||not-yet-due|